Second Wockhardt Plant Banned By U.S. FDA For Alleged GMP Violations
This article was originally published in PharmAsia News
Executive Summary
A second Wockhardt plant producing drugs for the U.S. market has been banned by the U.S. FDA for violating good-manufacturing practices.